Geneva, July 22 -- International Clinical Trials Registry received information related to the study (NCT06739122) titled 'A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)' on Dec. 13, 2024.

Study Type: Interventional

Study Design: Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Eli Lilly and Company

Condition: Type 2 Diabetes

Intervention: Drug: Dulaglutide

Recruitment Status: Recruiting

Phase: Phase 3

Date of First Enrollment: January 10, 2025

Target Sample Size: 55

Countries of Recruitment: United States

To know more, visit https://clinicaltrials.gov/ct2/sh...